Is Ansal Buildwell Ltd halal to invest in?

According to Musaffa's Shariah screening methodology, Ansal Buildwell Ltd (523007.BO) is currently classified as NOT HALAL as of January 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Ansal Buildwell Ltd a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Ansal Buildwell Ltd using these criteria to determine its compliance status.

Can Muslims buy shares of Ansal Buildwell Ltd?

Muslim investors may consider investing in Ansal Buildwell Ltd if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Ansal Buildwell Ltd classified as NOT HALAL?

Musaffa determines the Shariah status of Ansal Buildwell Ltd by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Ansal Buildwell Ltd updated?

The Shariah compliance status of Ansal Buildwell Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Ansal Buildwell Ltd become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Ansal Buildwell Ltd?

You can check the latest Shariah compliance status of Ansal Buildwell Ltd on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Ansal Buildwell Ltd 523007.BO

₹98.99 ₹0.11 (0.11%) 1D

Last Updated: May 15, 12:00 AM·BSE

523007.BO Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: January 27, 2026

Report Source: 2026 2nd Quarter Report

Ansal Buildwell Ltd. Stock Analysis 523007.BO

India Real Estate Nano Cap Report: Q2, 2026

Ansal Buildwell Ltd. engages in the provision of construction, real estate promotion, and development services. The firm is engaged in the business of promotion, construction and development of integrated townships, residential and commercial complexes, multistoried buildings, flats, houses, apartments, and others. The Company’s various projects include Florence Premium Floors, Sushant Lok Phase II/III; Ansal City, Amritsar; Royale Villas, Amritsar; Florence City, Pathankot; Ansal Basera City, Jhansi; Ansal City, Kochi; City Homes, Kochi; Sushant Tower, Gurugram, Sushant Lok Phase II/III; Navkriti Arcade, Gurugram, Sushant Lok Phase II/III; Boom Plaza, Gurugram, Sushant Lok Phase II/III; Gyan Bharati School, Saket, New Delhi, SAKET; Club Florence, Sector 56, Sushant Lok-II, Gurugram, Sushant Lok Phase II/III; Club Harmony, Sushant Lok-III, Gurugram, Sushant Lok Phase II/III; Riverdale Club, Kochi, Kerala, Kochi; C-Dot Main R&D Building Project, Delhi, Mehrauli; Covering of Palam Drain Project, Delhi, Dwarka and others.

Key Statistics of Ansal Buildwell Ltd (523007.BO)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

₹93.50₹99.89

Today's Open

₹98.88

Volume

7784.00

P/E Ratio (TTM)

8.34

52 Week Range

₹79.00₹157.70

Market Cap

708.53M

Avg. Volume

2831.18

Dividend Yield

1.11%

Financial Metrics & Statements of Ansal Buildwell Ltd (523007.BO)

FAQ's for Ansal Buildwell Ltd (523007.BO)

According to Musaffa’s Shariah screening methodology, Ansal Buildwell Ltd (523007.BO) is currently classified as NOT HALAL as of January 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.